Enjoy complimentary customisation on priority with our Enterprise License!
The renal biomarkers market share is expected to increase by USD 507.23 million from 2021 to 2026, at a CAGR of 7.40%.
This renal biomarkers market research report extensively covers renal biomarkers market segmentation by end-user (hospitals, clinics and diagnostic laboratories, and research laboratories) and geography (North America, Europe, Asia, and ROW). The renal biomarkers market report also offers information on several market vendors, including Abbott Laboratories, bioMerieux SA, BioPorto AS, F. Hoffmann-La Roche Ltd., IQVIA Holdings Inc., Randox Laboratories Ltd., RenalSense Ltd., Siemens AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc. among others.
Download the Free Report Sample to Unlock the Renal Biomarkers Market Size for the Forecast Period and Other Important Statistics
The rising prevalence of chronic kidney diseases is notably driving the renal biomarkers market growth, although factors such as limitations and complications involved in renal biomarkers may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the renal biomarkers industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Renal Biomarkers Market Driver
The rising prevalence of chronic kidney diseases is one of the key drivers supporting renal biomarkers market growth. Globally, the prevalence of chronic kidney diseases, including polycystic kidney disease, has seen a significant rise in recent years. The increasing prevalence of chronic kidney diseases can be attributed majorly to increased diabetes, high blood pressure (hypertension), heart disease, and people with a family member with kidney disease. Although polycystic kidney disease is one of the rare conditions, it is one of the substantial causes of chronic kidney diseases and potentially causes kidney failure. The strong prevalence of chronic kidney diseases is significantly contributed by the prevalence of polycystic kidney disease, as it is the major form of chronic kidney disease. Therefore, such an increasing prevalence of chronic kidney disease is driving the growth of the global renal biomarkers market during the forecast period.
Key Renal Biomarkers Market Trend
The growing awareness about kidney diseases is a trend that substantially impacts the market's growth. Various international and regional organizations are conducting programs to increase awareness about kidney diseases and enable the early diagnosis of the disease. For instance, the Kidney Disease Screening and Awareness Program (KDSAP) is a student-run organization in the US. This organization works in collaboration with physicians and community members to provide free kidney screenings and health education to underserved residents. Also, MRP participates in the Polycystic Kidney Disease Awareness Day on September 4 to spread awareness about the condition and available options for the treatment. Such initiatives are expected to increase awareness about kidney diseases and the available treatments during the forecast period.
Key Renal Biomarkers Market Challenge
The limitations and complications involved in renal biomarkers is hindering the renal biomarkers market growth. Biomarkers are complex and can offer various challenges and complications as vascular access dysfunction, activation of the coagulation system, and others that medical and nursing staff face daily while treating patients undergoing treatment. The non-standardization of biomarkers further limits the potential outcome improvements and dissemination of the therapy. Also, technical limitations such as the lack of interaction between the technician or medical staff, and the machines inhibit the quality of real-time data analytics being carried out. These limitations apply to how patients are clinically managed and how the technology is used. Such factors can hinder the growth of the global renal biomarkers market during the forecast period.
This renal biomarkers market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the renal biomarkers market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the renal biomarkers market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the renal biomarkers market encompasses successful business strategies deployed by the key vendors. The renal biomarkers market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The renal biomarkers market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the renal biomarkers market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
47% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for renal biomarkers market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The increasing number of support programs conducted by vendors and various organizations will facilitate the renal biomarkers market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the market in the region witnessed certain challenges owing to the COVID-19 outbreak. Countries such as the US, Canada, and Mexico were severely affected by the pandemic in the region. However, with the lifting of lockdowns in the latter part of 2020 and a rise in the number of new and rescheduled medical procedures, the demand for kidney stones medicines increased.
To gain further insights on the market contribution of various segments Request for a FREE sample
The renal biomarkers market share growth by the hospitals segment will be significant during the forecast period. Hospitals are the largest contributor of revenue to the global renal biomarkers market. The availability of skilled healthcare professionals with knowledge and expertise in providing adequate care attracts patients to hospitals. The increasing number of patients in hospitals due to the growth of the aging population has increased the use of renal biomarkers for detecting several types of kidney-related diseases.
This report provides an accurate prediction of the contribution of all the segments to the growth of the renal biomarkers market size and actionable market insights on post COVID-19 impact on each segment.
Neurological Biomarkers market - The market share is expected to increase to USD 6.00 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.43%.
Cardiac Biomarkers market - The market share is expected to grow steadily at a CAGR of almost 13% by 2021.
Renal Biomarkers Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Decelerate at a CAGR of 7.40% |
Market growth 2022-2026 |
$ 507.23 million |
Market structure |
Concentrated |
YoY growth (%) |
9.97 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 47% |
Key consumer countries |
US, Germany, UK, Canada, and France |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, bioMerieux SA, BioPorto AS, F. Hoffmann-La Roche Ltd., IQVIA Holdings Inc., Randox Laboratories Ltd., RenalSense Ltd., Siemens AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 08: Parent market
*Exhibit 09: Market characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis:Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
*2.2.7 Innovation
***3. Market Sizing
**3.1 Market segment analysis
*Exhibit 11: Market segments
**3.2 Market size 2021
**3.3 Market definition
*Exhibit 12: Offerings of vendors included in the market definition
**3.4 Market outlook: Forecast for 2021 - 2026
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
*Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2021 & 2026
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2021
***5 Market Segmentation by End-user
**5.1 Market segments
*Exhibit 22: End-user - Market share 2021-2026 (%)
**5.2 Comparison by End-user
*Exhibit 23: Comparison by End-user
**5.3 Hospitals - Market size and forecast 2021-2026
*Exhibit 24: Hospitals - Market size and forecast 2021-2026 ($ million)
*Exhibit 25: Hospitals - Year-over-year growth 2021-2026 (%)
**5.4 Clinics and diagnostic laboratories - Market size and forecast 2021-2026
*Exhibit 26: Clinics and diagnostic laboratories - Market size and forecast 2021-2026 ($ million)
*Exhibit 27: Clinics and diagnostic laboratories - Year-over-year growth 2021-2026 (%)
**5.5 Research laboratories - Market size and forecast 2021-2026
*Exhibit 28: Research laboratories - Market size and forecast 2021-2026 ($ million)
*Exhibit 29: Research laboratories - Year-over-year growth 2021-2026 (%)
**5.6 Market opportunity by End-user
*Exhibit 30: Market opportunity by End-user
***6. Customer landscape
**6.1 Overview
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
*Exhibit 31: ?Customer landscape?
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 32: Market share by geography 2021-2026 (%)
**7.2 Geographic comparison
*Exhibit 33: Geographic comparison
**7.3 North America - Market size and forecast 2020-2025
*Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
*Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
**7.4 Europe - Market size and forecast 2020-2025
*Exhibit 36: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 37: Europe - Year-over-year growth 2020-2025 (%)
**7.5 Asia - Market size and forecast 2021-2026
*Exhibit 38: Asia - Market size and forecast 2021-2026 ($ million)
*Exhibit 39: Asia - Year-over-year growth 2021-2026 (%)
**7.6 ROW - Market size and forecast 2020-2025
*Exhibit 40: ROW - Market size and forecast 2020-2025 ($ million)
*Exhibit 41: ROW - Year-over-year growth 2020-2025 (%)
**7.7 Key leading countries
*Exhibit 42: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 43: Market opportunity by geography
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Rising prevalence of chronic kidney diseases
*8.1.2 Increase in incidence of acute kidney injury (AKI) and associated risk factors
*8.1.3 Rapid increase in the aging population
**8.2 Market challenges
*8.2.1 Limitations of and complications involved in renal biomarkers
*8.2.2 Stringent regulatory guidelines
*8.2.3 High cost of treatment
*Exhibit 44: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Increasing awareness about kidney diseases
*8.3.2 Opportunities in emerging markets
*8.3.3 Focus on miniaturization and wearable technology and that for infant and pediatric applications
***9. Vendor Landscape
**9.1 Overview
*Exhibit 45: Vendor landscape
*The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
**9.2 Landscape disruption
*Exhibit 46: ?Landscape disruption?
*Exhibit 47: Industry risks
**9.3 Competitive Scenario
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 48: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 49: ?Market positioning of vendors?
**10.3 Abbott Laboratories
*Exhibit 50: Abbott Laboratories - Overview
*Exhibit 51: Abbott Laboratories - Business segments
*Exhibit 52: Abbott Laboratories - Key news
*Exhibit 53: Abbott Laboratories - Key offerings
*Exhibit 54: Abbott Laboratories - Segment focus
**10.4 bioMerieux SA
*Exhibit 55: bioMerieux SA - Overview
*Exhibit 56: bioMerieux SA - Business segments
*Exhibit 57: bioMerieux SA - Key news
*Exhibit 58: bioMerieux SA - Key offerings
*Exhibit 59: bioMerieux SA - Segment focus
**10.5 BioPorto AS
*Exhibit 60: BioPorto AS - Overview
*Exhibit 61: BioPorto AS - Product and service
*Exhibit 62: BioPorto AS - Key offerings
*10.6 F. Hoffmann-La Roche Ltd.
*Exhibit 63: F. Hoffmann-La Roche Ltd. - Overview
*Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
*Exhibit 65: F. Hoffmann-La Roche Ltd. - Key news
*Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
*Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
**10.7 IQVIA Holdings Inc.
*Exhibit 68: IQVIA Holdings Inc. - Overview
*Exhibit 69: IQVIA Holdings Inc. - Business segments
*Exhibit 70: IQVIA Holdings Inc. - Key offerings
*Exhibit 71: IQVIA Holdings Inc. - Segment focus
**10.8 Randox Laboratories Ltd.
*Exhibit 72: Randox Laboratories Ltd. - Overview
*Exhibit 73: Randox Laboratories Ltd. - Product and service
*Exhibit 74: Randox Laboratories Ltd. - Key offerings
**10.9 RenalSense Ltd.
*Exhibit 75: RenalSense Ltd. - Overview
*Exhibit 76: RenalSense Ltd. - Product and service
*Exhibit 77: RenalSense Ltd. - Key offerings
**10.10 Siemens AG
*Exhibit 78: Siemens AG - Overview
*Exhibit 79: Siemens AG - Business segments
*Exhibit 80: Siemens AG - Key offerings
*Exhibit 81: Siemens AG - Segment focus
**10.11 SphingoTec GmbH
*Exhibit 82: SphingoTec GmbH - Overview
*Exhibit 83: SphingoTec GmbH - Product and service
*Exhibit 84: SphingoTec GmbH - Key news
*Exhibit 85: SphingoTec GmbH - Key offerings
**10.12 Thermo Fisher Scientific Inc.
*Exhibit 86: Thermo Fisher Scientific Inc. - Overview
*Exhibit 87: Thermo Fisher Scientific Inc. - Business segments
*Exhibit 88: Thermo Fisher Scientific Inc. - Key news
*Exhibit 89: Thermo Fisher Scientific Inc. - Key offerings
*Exhibit 90: Thermo Fisher Scientific Inc. - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 Notes and Caveats
**11.2 Currency conversion rates for US$
*Exhibit 91: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 92: ?Research Methodology
*Exhibit 93: ??Validation techniques employed for market sizing?
*Exhibit 94: ??Information sources
**11.4 List of abbreviations
*Exhibit 95: List of abbreviations
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.